침습성 프로락틴 분비 뇌하수체 선종에서 Bromocriptine의 치료효과

The Effect of Bromocriptine Treatment for Invasive Prolactinoma

  • 양문술 (연세대학교 의과대학 신경외과학교실) ;
  • 김선호 (연세대학교 의과대학 신경외과학교실) ;
  • 임승길 (연세대학교 의과대학 내과학교실) ;
  • 이승구 (연세대학교 의과대학 방사선과학교실)
  • Yang, Moon-Sool (Departments of Neurosurgery, Yonsei University College of Medicine) ;
  • Kim, Sun-Ho (Departments of Neurosurgery, Yonsei University College of Medicine) ;
  • Lim, Seung-Gil (Departments of Endocrinology, Yonsei University College of Medicine) ;
  • Lee, Seung-Koo (Departments of Diagnostic Radiology, Yonsei University College of Medicine)
  • 발행 : 2005.04.30

초록

Objective: The prolactinoma is the most common pituitary tumor and sometimes shows severe invasiveness to the adjacent cavernous sinus, especially in the male patient. The dopamine agonist can be used as an alternative treatment modality to surgery. But, the transsphenoidal or transcranial approach for tumor removal has been more preferred treatment option of neurosurgeons in invasive prolactinoma. Especially rapid decompression of mass effect and resolution of the neurologic deficit is demanded. The prospective study is done in order to identify the therapeutic efficacy of bromocriptine as an initial treatment option for the invasive prolactionomas. Methods: Twenty patients with invasive prolactinoma were studied. Preoperative neurological and endocrinological evaluations were done, and size and invasiveness of the tumor was estimated on MRI. Bromocriptine was administrated by increasing dose planning reaching maximum dose at 1 month of treatment, with close neurological and endocrinological monitoring. At 3months after treatment, MRI was taken and decision was made whether to continue bromocriptine or to have surgical intervention. Results: Thirteen patients showed excellent result with only bromocriptine treatment. These patients showed not only marked reduction of tumor volume and prolactin level, but also, improving clinical symptoms and other hormonal deficits. 13patients who had visual field defect and decreased visual acuity had all improved visual symptoms. But, the remaining 4patients required surgical treatment due to insufficient reduction of tumor size inspite of normalized prolactin level within 3months. Remaining 2patients had $20{\sim}30%$ of tumor size reduction, but prolactin level was not normalized. One patient required radiation therapy. Conclusion: Bromociptine can be used as initial treatment for the invasive prolactinomas with careful monitoring of the neurological and endocrinological status. It should be carefully followed up for tumor size reduction within 3 months after initiation of treatment.

키워드

참고문헌

  1. Acquati S, Pizzocaro A, Tomei G, Giovanelli M, Libe R, Faglia G, et al : A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurosurg Sci 45 : 65-69, 2001
  2. Barrow DL, Mizuno J, Tindall GT : Management of prolactinoma associated with Very high serum prolactin levels. J Neurosurg 68 : 554-558, 1988 https://doi.org/10.3171/jns.1988.68.4.0554
  3. Enrica C, Franco C : Diagnosis and drug therapy of prolactinoma. Drugs 51 : 954-963, 1996 https://doi.org/10.2165/00003495-199651060-00004
  4. Franks S, Jacobs HS, Nabarro JDN : Studies of prolactin in pituitary disease. J Endocrinol 67 : 55, 1975
  5. Hubbard JL, Scheithauer BW, Abboud CF, Laws ER Jr : Prolactinsecreting adenomas. The preoperative response to bromocriptine treatment and surgical outcome. J Neurosurg 67 : 816-821, 1987 https://doi.org/10.3171/jns.1987.67.6.0816
  6. Iwai Y, Hakuba A, Khosla VK, Nishikawa M, Kazuyama J, Inoue Y, et al : Giant basal prolactinoma extending into the nasal cavity. Surg Neurol 37 : 280-283, 1992 https://doi.org/10.1016/0090-3019(92)90153-E
  7. Jeon WY, Kim OL, Kim SH, Bae JH, Cho SH : The Surgical Result of Pituitary Adenoma by Trassphenoidal Approach. J Korean Neurosurg Soc 30 : 1278-1283, 2001
  8. Joseph JP, Laurence K, Daniel CD, Donna KP, Caleb SM, Anne K : Primary medical therapy of micro-and macroprolactinomas in Men. J Clin Endocrinol Metab 85 : 3053-3057, 2000 https://doi.org/10.1210/jc.85.9.3053
  9. Jung TY, Kim JH, Kim IU, Kim TS, Jung S, Kim SH : Surgical Outcome of Pituitary Prolactinomas. J Korean Neurosurg Soc 32 : 307-311, 2002
  10. Kwon TH, Chung YG, Cho TH, Park JY, Park YK, Chung HS, et al : Prolactinoma : Surgical Treatment and Outcome. J Korean Neurosurg Soc 27 : 357-362, 1998
  11. Landolt AM, Vance ML, Reilly PL : Pituitary adenomas. ed 1. New York : Churchill Livingstone : 1992
  12. Lee KH, Kim DH, Kim IS : Transcavernous Approach for invasive pituitary adenoma. J Korean Neurosurg Soc 35 : 53-59, 2004
  13. Mark EM, Richard LE, Richard EB, Burton C, Chang RJ, Robert J, et al : Bromocriptine as Primary Therapy for Prolactin-Secreting macroadenomas, Results of a Prospective Multicenter study. J Clin Endocrinol Metab 60 : 698-705, 1985 https://doi.org/10.1210/jcem-60-4-698
  14. Naokatsu S, Michio N, Kenro S, Akira Y : Surgical indication after bromocriptine therapy on giant prolactinoma: Effects and limitation of the medical treatment. Endocrine journal 45 : 529-537, 1998 https://doi.org/10.1507/endocrj.45.529
  15. Nelson PB, Goodman M, Maroon JC, Martinez AJ, Moossy J, Robinson AG : Factors in predicting outcome from operation in patients with prolactin secreting pituitary adenomas. Neurosurgery 13 : 634-641, 1983 https://doi.org/10.1227/00006123-198312000-00002
  16. Raj KS, Marc SA, Wesley AK, Kalmon DP : Giant prolactinomas : clinical management and long-term follow up. J Neurosurg 97 : 299- 3063, 2002 https://doi.org/10.3171/jns.2002.97.2.0299
  17. Schcart WA : Implication of very high prolactin levels associated with pituitary tumors. J Neurosurg 52 : 226-228, 1980 https://doi.org/10.3171/jns.1980.52.2.0226
  18. Schlechte J, Sherman B, Halmi N, VanGilder J, Chapler F, Dolan K, et al : Prolactin-secreting pituitary tumors in amenorrheic women : a comprehensive study. Endocri Rev 1 : 295-308, 1980 https://doi.org/10.1210/edrv-1-3-295
  19. Serri O, Rasio E, Beauregard H, Hardy J, Somma M : Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Eng. J Med 309 : 280-283, 1983
  20. Tindall GT, McLanahan S, Christy JH : Transsphenoidal microsurgery for pituitary tumors associated with hyperprolactinemia. J Neurosurg 48 : 849-860, 1978 https://doi.org/10.3171/jns.1978.48.6.0849
  21. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB : Transsphenoidal microsurgical therapy of prolactinomas : initial outcomes and long-term results. Neurosurgery 44 : 254-257, 1999 https://doi.org/10.1097/00006123-199902000-00006